Therapy (HCV)
"Combination Therapy With Thymosin alpha 1 and Interferon for the Treatment of Chronic Hepatitis C Infection: A Randomized, Placebo-Controlled Double-Blind Trial."
Published in Hepatitis Weekly, May 11th, 1998
According to the authors' abstract of an article published in Hepatology, "Hepatitis C is a major cause of liver disease leading to cirrhosis. Although interferon (IFN) is the only approved therapy treatment, it is characterized by low response rates and dose-limiting side effects. We evaluated the addition of thymosin alpha 1 (TA1), an immunomodulatory peptide, to the standard treatment regimen for hepatitis C to determine if combination therapy shows biological activity using outcome measures including normalization of alanine aminotransferase levels, histological activity, and viral load during treatment. We performed a randomized, double-blind, placebo-controlled trial to compare...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
Source: Hepatitis Weekly (1998-05-11)
More Articles from Hepatitis Weekly
- Immunity (HBV)
Anti-HBc Does Not Preclude Hepatitis B Vaccination - Pathogenesis (HCV)
Cryopathic Process Probably Not Involved in Liver Disease - Therapy
Lamivudine Resistance Differs in HIV+ and HBV+ - Transmission (HBV)
Neonatal HBV Strain is Generally Identical to Mothers' - Transmission (HGV)
Neonatal HGV Infection is Usually Persistent - Antiviral Therapy (HBV)
Disabling Formation of Viral Envelope May Help Reduce HBV, HCV Infection - More from this issue of Hepatitis Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
